ChemoMetec A/S (CPH:CHEMM)
414.00
-6.60 (-1.57%)
At close: Mar 6, 2026
ChemoMetec Revenue
ChemoMetec had revenue of 249.01M DKK in the half year ending December 31, 2025, with 24.63% growth. This brings the company's revenue in the last twelve months to 493.12M, up 7.31% year-over-year. In the fiscal year ending June 30, 2025, ChemoMetec had annual revenue of 495.57M with 21.50% growth.
Revenue (ttm)
493.12M
Revenue Growth
+7.31%
P/S Ratio
14.61
Revenue / Employee
2.87M
Employees
172
Market Cap
7.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 495.57M | 87.70M | 21.50% |
| Jun 30, 2024 | 407.87M | -36.53M | -8.22% |
| Jun 30, 2023 | 444.40M | 16.01M | 3.74% |
| Jun 30, 2022 | 428.39M | 147.26M | 52.38% |
| Jun 30, 2021 | 281.13M | 67.03M | 31.31% |
| Jun 30, 2020 | Pro | Pro | Pro |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novo Nordisk | 309.06B |
| Genmab | 23.66B |
| Coloplast | 27.89B |
| ALK-Abelló | 6.31B |
| H. Lundbeck | 24.63B |
| Zealand Pharma | 9.21B |
| Ambu A/S | 6.09B |
| Bavarian Nordic | 6.89B |
ChemoMetec News
- 4 months ago - Full Year 2025 Chemometec A/S Earnings Call Transcript - GuruFocus
- 1 year ago - Half Year 2025 Chemometec A/S Earnings Call Transcript - GuruFocus